Dietary Fibre and Chromium Picolinate Efficacy in Overweight and Obese Women (DFCP)

Impact of Dietary Fibre and Chromium Picolinate on Satiety, Satiation, Weight Loss and Gut Microbiome Composition in Overweight and Obese Women

Obesity is one of the greatest causes of preventable morbidity and mortality worldwide with the main treatments requiring significant changes to lifestyle, particularly dieting and physical exercise. Glucomannan is a dietary fibre that expands in the stomach, creating the feeling of fulness, while chromium can regulate insulin response.

Study Overview

• Status: Completed
• Conditions: Obesity; Overweight
• Intervention / Treatment: Dietary supplement: agglomerated glucomannan, oligofructose and chromium mixture

Detailed Description

The aim of this pilot study was to investigate the effect of agglomerated glucomannan, oligofructose and chromium, as part of a calorie restricted diet plan, on weight loss, satiety, satiation, mood and gut microbiome composition in a human intervention study.

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • UK
    • London, UK, United Kingdom, SW15 4JD
      • Health Sciences Research Centre, Life Sciences Department, University of Roehampton

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 22 years to 70 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• healthy female
• aged 18-65 years
• with a BMI between 25 and 35 kg/m2
• not dieting within the previous four months
• not having lost > 5% body weight in the previous year
• not having increased physical activity levels in the past 2-4 weeks
• intending to modify them during the study
• able to eat most everyday foods

Exclusion Criteria:

• BMI < 25 kg/m2
• > 35 kg/m2
• significant health problems
• taking any medication or supplements known to affect appetite
• weight within the past month and/or during the study
• pregnant, planning to become pregnant or breastfeeding
• history of anaphylaxis to food
• known allergies or intolerance to foods and/or to the study materials or any of their stated ingredients.
• Volunteers who were on specific food avoidance diets
• with abnormal eating behaviour
• receiving systemic or local treatment likely to interfere with the evaluation of the study parameters
• smokers and those who have recently ceased smoking
• Volunteers who work in appetite or feeding related areas volunteers who participated in another experimental study or receipt of

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

EXPERIMENTAL: Glucomannan, oligofructose and chromium mixture; Agglomerated glucomannan, oligofructose and chromium mixture as the functional ingredient in a calorie

Dietary supplement: agglomerated glucomannan, oligofructose and chromium mixture; Participants visited the University of Roehampton on three separate occasions: visit 1 (screening), visit 2 (baseline), and visit 3 (end of the trial) in total over a period of 4-weeks. During the 4-week study period, participants were instructed to replace breakfast and lunch with a shake (206 kcal/shake) each delivering 3g of the active ingredient (Mix: agglomerated glucomannan, oligofructose and chromium picolinate), and one snack bar each delivering 1.5g of the active ingredient (112 kcal/bar) in between breakfast and lunch, and lunch and dinner following by a selection of healthy dinner according to standard nutritional guidance not exceeding 1500 kcal/day. All subjects were instructed to prepare shakes by using a shaker or blender by mixing all ingredients with 200 ml of water. Participants were also instructed to consume all shakes and bars with an extra 200 ml glass of water throughout the study period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Weight loss changes from the baseline to 4 weeks intervention	The body mass was measured to the nearest 0.1 kg using a digital balance scale (Seca 707, Seca Corporation, Hamburg, Germany)	To test, in humans, changes in body weight from the baseline to 4 weeks intervention
Body mass index changes from the baseline to 4 weeks intervention	Body mass index was determined as weight divided by height squared (kg/m^2)	To test, in humans, changes in body mass index (calculated in Kg/m^2) from the baseline to 4 weeks intervention
Blood pressure changes from the baseline to 4 weeks intervention	Blood pressure was measured using a digital blood pressure monitor (Nissei, model DS-1902, Japan Precision Instruments, Inc., Gunma, Japan).	To test, in humans, changes in blood pressure (calculated in mm/Hg) from the baseline to 4 weeks intervention
Body composition changes from baseline to 4 weeks intervention	Body fat percentage was assessed after a 12-hour water-only fast by bioelectrical impedance analysis (BIA) method, using a Tanita BC-418 MA Segmental Body Composition Analyser, which incorporates eight tactile electrodes (Tanita Corporation, Tokyo, Japan).	To test, in humans, changes in body fat percentage (calculated in %) from the baseline to 4 weeks intervention
Waist circumference changes from baseline to 4 weeks intervention	Waist was assessed using anthropometric tape (Seca 201, Hamburg, Germany) over light clothing to the nearest 0.1 centimetre while the subjects were in the standing position at the end of gentle expiration. The waist circumference was measured at the mid-point between the lowest rib margin and anterior superior iliac crest and hip circumference was measured at the maximum protuberance of the buttocks, and the waist-to-hip ratio was calculated by dividing waist circumference by hip circumference.	To test, in humans, changes in waist circumference (calculated in cm) from the baseline to 4 weeks intervention
Resting metabolic rate changes from baseline to 4 weeks intervention	Resting metabolic rate (RMR) before and at the end of the 4-week intervention was determined by indirect calorimetry using the breath-by-breath system of recording (Cortex MetaLyzer 3B device).	To test, in humans, changes in resting metabolic rate (calculated Kcal) from the baseline to 4 weeks intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
DNA Gut microbiome diversity changes from baseline to 4 weeks intervention	Sequencing was performed on an Illumina MiSeq desktop sequencer using the MiSeq Reagent Kit V2 (Illumina, San Diego). The significance in the abundance of the relevant taxa were validated by Wilcoxon signed-rank tests (16s rRNA sequencing using Illumina MiSeq Platform and QIIME data analysis software).	To test, in humans, changes in the faecal microbiota composition and microbial activity of the volunteers using DNA profiling in faeces from the baseline to 4 weeks
Hunger, mood and cravings changes from baseline to 4 weeks intervention	Changes in hunger, mood and craving was determined via Control of Eating Questionnaire (CoEQ) comprised of twenty items to assess the intensity and type of food cravings each participant experienced over the previous 7 days, as well as subjective sensations of appetite and mood. Responses were recorded using the visual analogue scale.	To test, in humans, changes in hunger, mood and cravings (questionnaire based analysis) from the baseline to 4 weeks intervention

Collaborators and Investigators

• Sponsor: University of Roehampton
• Investigators: Study Director: ADELE COSTABILE, Dr, Roehampton University

Study record dates

Study Major Dates

• Study Start (ACTUAL): March 12, 2018
• Primary Completion (ACTUAL): August 30, 2018
• Study Completion (ACTUAL): September 30, 2018

Study Registration Dates

• First Submitted: January 24, 2020
• First Submitted That Met QC Criteria: January 29, 2020
• First Posted (ACTUAL): January 31, 2020

Study Record Updates

• Last Update Posted (ACTUAL): January 31, 2020
• Last Update Submitted That Met QC Criteria: January 29, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Keywords: weight loss; microbiota; mood; hormones; hunger
• Additional Relevant MeSH Terms: Body Weight; Overweight; Physiological Effects of Drugs; Gastrointestinal Agents; Trace Elements; Micronutrients; Cathartics; Chromium; (1-6)-alpha-glucomannan
• Other Study ID Numbers: LSC 18/238

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No